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(KM) estimate [2] . It estimates the probability of a failure in the absence of the competing risk -it mathematically factors it out. The second and increasingly common method of assessing failure rates is by using the cumulative incidence (CI) curve to estimate the probability of failures actually observed in patients who are subject to censoring by the competing risk [3] . The crux of the distinction between the italicized phrases lies in the effect of the competing risk on the estimates: it doesn't change the Kaplan-Meier curve (besides reducing the effective sample size); but by removing patients from being subject to failure, it will lower the cumulative incidence. Two examples should render this point intelligible.
The first example consists of what academics prefer to call a "spirited discussion" in the pages of the Red Journal. In 1994 Caplan, et al. [4] launched a firm critique of the Kaplan-Meier (KM) curve for estimating rates of cause-specific failures such as late complications of radiation. They point out that the KM estimates of component causes of failure would sum to more than the KM estimate of any cause. This is correct: to take an extreme example, with sufficient follow-up the KM estimate of cause of death due to heart disease would eventually equal one, or nearly so, as would the estimates of death due to cancer, kidney disease, etc. These clearly sum to more than unity, the all cause long-term probability of death [5] . This is because the KM curve estimates probabilities of one failure in the absence of any others. On the other hand, the CI curves of each of these causes of death will sum to the CI of any death. Caplan, et al. concluded that KM analysis of cause-specific failure "should be avoided … in favor of appropriate methods [CI curves]." Bentzen, et al. [6] and Denham, et al. [7] equally strongly endorsed KM in their rebuttal. Their logic, summarized by Bentzen et al., was that "The reason is that this type of estimate [the CI function] is not specific for the endpoint of interest but is affected by the risk of the competing events as well." That is, if a late complication is uncommon because most patients die of their disease then the cumulative incidence will be low while the KM could be high: remember, KM estimates late complication rates only among survivors. (The only point which all authors held in common was their dislike of giving crude proportions, that is the total fraction of patients who had late toxicities. These figures are not adjusted for follow-up in any way; thus shorter studies have lower rates.) Which method is preferable? It depends on the use to which the results are to be put. Chappell [8] , in an attempt to get in the last word, asked readers to consider a nonce example in which a population of patients has an 80% mortality rate during the first year of disease with no subsequent events. Suppose also that all survivors exhibit complications by three years. Then CI would give a 20% estimate of gross toxicity at three years along with an 80% estimate of death. That is, only 20% of patients will have toxicities because the rest died too soon. KM, on the other hand, would estimate a 100% toxicity rate among patients who survive three years as well as the 80% mortality. This is no contradiction -the choice depends on the status of the competing risk, death. To a radiation biologist or other theorist seeking to characterize the toxicity process (perhaps out of interest in applying the same regimen to a different group of patients with better prognoses), death is a nuisance to be factored out and KM would be the right method. But to a patient or physician, death is a quite relevant event and the low chance of toxicity as estimated by CI might be worth possibly extending quality or quantity of life.
I end with a numerical example taken from Klein & Moeschberger [9] , to whom I recommend the reader who wants a more thorough explanation of the data and calculations. They consider outcomes among 38 patients who received bone marrow transplant for ALL. The time scale is days after transplant, and one quantity of interest is the chance of a patient dying in remission. The opportunity for this failure to occur is clearly obviated by recurrence as a competing risk. The KM and CI estimates are plotted in the Figure ( because KM curves traditionally start at one and decrease to zero, one minus KM is shown here for comparability). We see that, as is generally the case, KM exceeds CI. This is because KM estimates the probability of death in remission assuming no relapse occurs, and CI estimates the probability of death in remission among all patients whose pattern of relapses is similar to that observed in our data. The CI curve is naturally lower because relapsed patients count as a "success" (in terms of death in relapse), while for the KM curve they are eliminated from consideration. The preference again depends upon the question which is being asked and the purposes to which the answer will be put. CI gives the "real-world" chances of an event and KM is more informative about the medical processes involved in treatment-related mortality. Figure   Figure 1 . Estimated probability of death in remission via CI and KM method ALL transplant data of Klein and Moeschberger. Cumulative incidence (dashed) and one minus Kaplan-Meier (solid) curves for the probability of death in remission using the bone marrow transplant in acute lymphoblastic leukemia data of Klein and Moeschberger [9] . 
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